Folliclever

In-depth read

GLP-1 Hair Loss: How Common It Is and Why It Happens

Started a weight-loss shot and now there's more hair in your brush? Here's what the research says about how often it happens, why, and whether it comes back.

Reviewed by Steve9 min read

A woman with wavy auburn hair sits at a kitchen table in morning light, holding a mug and looking out the window.

The short version

  • In the trials behind the FDA labels, about 3% of adults on semaglutide and 4% to 5% on tirzepatide reported hair loss, compared with about 1% on placebo [1][2].
  • In the tirzepatide trials, women reported hair loss far more often than men (7.1% vs. 0.5%), and the label links it to weight reduction [2].
  • Most of what researchers describe is a shedding pattern called telogen effluvium, which typically shows up 2 to 4 months after a trigger and tapers over 6 to 9 months in most cases [8][9].
  • If you think a medicine is behind your shedding, the American Academy of Dermatology says to talk with your doctor rather than stop it suddenly [7].

Maybe it started a few months after your first injection. More hair in the shower drain, a ponytail that feels thinner, strands all over your sweater. If you take a GLP-1 medicine for weight or blood sugar, you've probably wondered whether GLP-1 hair loss is what you're seeing.

The short answer: GLP-1 hair loss is real, but it's uncommon. In the large trials behind the FDA labels, hair loss was reported by about 3% of adults on semaglutide and 4% to 5% on tirzepatide, versus about 1% on placebo [1][2]. Most of what researchers describe looks like temporary shedding tied to weight loss, not lasting damage to hair follicles [6][9].

Below: how common it is, who seems most affected, why it happens, the usual timeline, and how to tell a shedding phase from normal hair fall.

3% vs. 1%

Adults reporting hair loss on semaglutide vs. placebo in weight-loss trials[1]

7.1% vs. 0.5%

Women vs. men reporting hair loss on tirzepatide in two pooled trials[2]

2–4 months

Usual delay between a trigger and noticeable shedding (telogen effluvium)[8]

Does GLP-1 medicine cause hair loss?

The evidence points to a real link, with a small absolute risk. A 2026 meta-analysis pooled nine studies, seven of them randomized trials, covering 4,114 people taking GLP-1 medicines [3]. Hair loss was about three times as likely as on placebo (risk ratio 3.25), and 3.9% of users reported it [3].

A second 2026 meta-analysis looked only at randomized semaglutide trials. Hair loss was reported by 191 of 11,564 people on semaglutide and 36 of 9,799 people in comparison groups [4]. The authors rated that evidence low-certainty, partly because not every trial recorded hair loss completely [4].

Health records tell a similar story. A 2026 BMJ study at one US health system compared about 12,000 adults with type 2 diabetes who started a GLP-1 medicine against people starting two other kinds of diabetes drugs [5]. The GLP-1 group was more likely to get a new hair-loss diagnosis (hazard ratios 1.37 and 1.68), and the link was specific to non-scarring hair loss [5]. The authors stress that the absolute risk is low [5].

Some limits are worth knowing. The big weight-loss trials for both drugs, such as STEP 1 and SURMOUNT-1, were paid for by the companies that make them [11][12]. Records studies rely on diagnosis codes and can show a link, but they can't fully prove the medicine caused it [5][6].

How common is hair loss on GLP-1 medicines?

Across the main studies, the share of people reporting hair loss on these medicines ranges from under 2% to about 5%, depending on the drug and how carefully each trial asked [1][2][4]. Here's how the numbers line up.

Hair loss on GLP-1 medicines: what different studies found
StudyWho was studiedHair loss reported
Semaglutide label trials [1]2,116 adults on the drug, 1,261 on placebo3% vs. 1% on placebo
Tirzepatide label trials [2]Adults with obesity or overweight, two pooled trials4% to 5% vs. 1% on placebo
Meta-analysis, 2026 [3]4,114 GLP-1 users in 9 studies3.9% of users; about 3 times placebo
Semaglutide trial meta-analysis, 2026 [4]11,564 on semaglutide, 9,799 comparators191 vs. 36 people (about 1.7% vs. 0.4%)

One pattern stands out: women. In the two pooled tirzepatide trials, 7.1% of women on the drug reported hair loss, compared with 0.5% of men [2]. A 2026 review found that female sex and losing more than 10% of body weight were the most consistent predictors across studies [9]. Why women are more affected hasn't been worked out.

Hair loss reported in two pooled tirzepatide trials, by sex (%)
  • Women, placebo1.3%
  • Women, tirzepatide7.1%
  • Men, placebo0%
  • Men, tirzepatide0.5%

Percent of each group reporting hair loss as a side effect.

Source: [2] U.S. Food and Drug Administration via DailyMed (National Library of Medicine), 2026

Show the numbers
Hair loss reported in two pooled tirzepatide trials, by sex
Women, placebo1.3%
Women, tirzepatide7.1%
Men, placebo0%
Men, tirzepatide0.5%

Why would a weight-loss medicine cause hair shedding?

The leading explanation is the weight loss itself. Hair follicles take turns growing and resting. Normally about 15% of scalp hairs are resting, but a shock to the body can push as many as 70% of growing hairs into rest at once, and they fall out a few months later [8]. Doctors call this telogen effluvium [7][8].

Fast or large weight loss is a known trigger. The American Academy of Dermatology lists losing 20 pounds or more among the stressors behind heavy shedding, along with giving birth and major stress [7]. DermNet lists weight loss, unusual diets and nutritional deficiencies such as low iron [8].

The GLP-1 data fit that picture. The tirzepatide label says hair loss in its trials was associated with weight reduction [2]. In a 2026 records study, people on semaglutide or tirzepatide who developed hair loss had a lower BMI at follow-up than those who didn't, and the clearest signal was for telogen effluvium [6]. Alopecia areata, an immune condition the researchers used as a check, showed no link [6].

Whether these drugs also act on hair follicles directly is still open. A 2026 review concluded that shedding is driven mainly by how much and how fast weight comes off, rather than by drug toxicity [9]. That's a review of existing studies, though, not a new experiment designed to answer the question.

When does GLP-1 hair loss start, and does it grow back?

It usually starts a few months into weight loss and settles within the following months. The studies we found don't give a timeline specific to these medicines, so the best guide is the general pattern of telogen effluvium [8].

The usual course of telogen effluvium
  1. Month 0

    A trigger

    Fast weight loss, illness, surgery, childbirth or major stress pushes many growing hairs into their resting phase [8].

  2. Months 2 to 4

    Shedding becomes noticeable

    Increased hair fall usually becomes noticeable 2 to 4 months after the trigger [8].

  3. Months 6 to 9

    Shedding tapers off

    In most cases the hair fall settles and the scalp fills back in, though recovery can be incomplete for some [8].

  4. Longer

    If the trigger continues

    Ongoing stress can keep shedding going for a long time, which doctors call chronic telogen effluvium [7][8].

Because shedding lags behind its cause, it can arrive just as your weight loss is going well. When you're trying to work out what set it off, think back two to four months [8].

How can you tell real shedding from normal hair fall?

Start with the baseline: losing 50 to 100 hairs a day is normal, according to the American Academy of Dermatology [7]. Loose hairs collect between washes and come out together, which can look alarming even when your daily total hasn't changed.

Shedding and thinning aren't the same thing either. Shedding means more hairs are falling out than usual. Hair loss, in the AAD's terms, happens when something stops hair from growing [7].

The mirror is a poor judge of either. Lighting, a new haircut or wet hair can make the same scalp look very different from one week to the next. Photos taken the same way, of the same spots, every few weeks give you something steadier to compare, and something concrete to show a doctor.

What should you do if your hair is shedding on a GLP-1?

Start with a conversation, not a decision to quit. The AAD advises talking with your doctor if you suspect a medicine is behind your hair loss, and warns against stopping on your own [7].

“Serious side effects can occur if you immediately stop a treatment or drug.”
— American Academy of Dermatology, patient guidance on hair shedding[7]

Shedding also has plenty of causes besides the medicine. DermNet lists thyroid disorders, low iron, illness, other medications and stress among the triggers [8]. A dermatologist can sort out which kind of hair loss you have, and a 2026 review urges doctors to counsel patients, look at nutrition during weight loss, and avoid stopping a GLP-1 too early over shedding [10].

Whether and how to treat the hair itself is a decision for a dermatologist, after they've confirmed what's going on.

If you're seeing more hair in the drain right now, the worry makes sense. What the research describes most often is a phase rather than a permanent change. Note when it started, keep an eye on it in a steady way, and bring what you've noticed to someone who can look at your scalp in person.

Questions people ask

Is hair loss from semaglutide reversible?

The shedding most linked to semaglutide and similar medicines is telogen effluvium, a non-scarring type that usually tapers back to normal over 6 to 9 months [8]. Recovery can be incomplete in some cases, and other kinds of hair loss can overlap, so see a dermatologist if shedding doesn't ease or your hair keeps getting thinner [8].

Does tirzepatide cause more hair loss than semaglutide?

On their FDA labels, hair loss was reported by 4% to 5% of adults on tirzepatide and 3% on semaglutide, each against about 1% on placebo [1][2]. Those numbers come from different trials, not a head-to-head comparison, so they can't settle the question. A 2026 review says tirzepatide shows stronger links than older drugs in this class, but a direct comparison with semaglutide is still needed [9].

Why do women seem to lose more hair on GLP-1 drugs?

In two pooled tirzepatide trials, 7.1% of women reported hair loss, compared with 0.5% of men [2]. A 2026 review found female sex and losing more than 10% of body weight were the most consistent predictors across studies [9]. Researchers haven't yet explained why women are more affected, so for now it's an observed pattern.

Should I stop my GLP-1 if my hair is falling out?

Not on your own. The American Academy of Dermatology advises talking with your doctor if you suspect a medicine is causing hair loss, because stopping a drug suddenly can cause serious side effects [7]. A 2026 review also cautions doctors against stopping these medicines too early because of shedding [10]. Your prescriber and a dermatologist can weigh it together.

Sources

  1. 1.Semaglutide injection for chronic weight management: prescribing information (adverse reactions). U.S. Food and Drug Administration via DailyMed (National Library of Medicine), 2024.
  2. 2.Tirzepatide injection for weight reduction: prescribing information (adverse reactions). U.S. Food and Drug Administration via DailyMed (National Library of Medicine), 2026.
  3. 3.Glucagon-like peptide-1 receptor agonists and hair loss: A systematic review and meta-analysis. Diabetes Research and Clinical Practice, 2026.
  4. 4.Cutaneous Adverse Events With Semaglutide: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Cureus, 2026.
  5. 5.Risk of hair loss associated with glucagon-like peptide-1 receptor agonists in adults with type 2 diabetes: target trial emulation. BMJ, 2026.
  6. 6.Nonscarring Alopecia in Adults Treated With GLP-1s: A Propensity Score Matched TriNetX Cohort Study. The Laryngoscope, 2026.
  7. 7.Do you have hair loss or hair shedding?. American Academy of Dermatology.
  8. 8.Telogen effluvium. DermNet.
  9. 9.GLP-1 receptor agonists and hair loss: adverse effect, epiphenomenon, or therapeutic paradox?. Acta Diabetologica, 2026.
  10. 10.GLP-1 Receptor Agonists and Alopecia: A Systematic Review and Meta-Analysis of Incidence, Risk, Subtypes, and Mechanisms. Skin Appendage Disorders, 2026.
  11. 11.Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine, 2021.
  12. 12.Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine, 2022.

About this article

Researched and drafted with AI help, then checked and approved by Steve before it went live. Steve: Founder @ Folliclever. Every number links to its source above.

This is general information, not medical advice, and Folliclever doesn't diagnose. For anything about your own hair or scalp, talk to a dermatologist.